Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting cancer cell dormancy.
Agudo J, Aguirre-Ghiso JA, Bhatia M, Chodosh LA, Correia AL, Klein CA. Agudo J, et al. Nat Rev Cancer. 2024 Feb;24(2):97-104. doi: 10.1038/s41568-023-00642-x. Epub 2023 Dec 7. Nat Rev Cancer. 2024. PMID: 38062251 Free PMC article.
SOX17 enables immune evasion of early colorectal adenomas and cancers.
Goto N, Westcott PMK, Goto S, Imada S, Taylor MS, Eng G, Braverman J, Deshpande V, Jacks T, Agudo J, Yilmaz ÖH. Goto N, et al. Among authors: agudo j. Nature. 2024 Mar;627(8004):636-645. doi: 10.1038/s41586-024-07135-3. Epub 2024 Feb 28. Nature. 2024. PMID: 38418875
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Keenan TE, et al. Among authors: agudo j. Nat Commun. 2021 Sep 21;12(1):5563. doi: 10.1038/s41467-021-25769-z. Nat Commun. 2021. PMID: 34548479 Free PMC article. Clinical Trial.
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Waks AG, et al. Among authors: agudo j. J Immunother Cancer. 2022 Oct;10(10):e005119. doi: 10.1136/jitc-2022-005119. J Immunother Cancer. 2022. PMID: 36252998 Free PMC article. Clinical Trial.
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Hermida-Prado F, et al. Among authors: agudo j. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711. Cancer Res. 2023. PMID: 37450351 Free PMC article.
cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes.
Roehle K, Qiang L, Ventre KS, Heid D, Ali LR, Lenehan P, Heckler M, Crowley SJ, Stump CT, Ro G, Godicelj A, Bhuiyan AM, Yang A, Quiles Del Rey M, Biary T, Luoma AM, Bruck PT, Tegethoff JF, Nopper SL, Li J, Byrne KT, Pelletier M, Wucherpfennig KW, Stanger BZ, Akin JJ, Mancias JD, Agudo J, Dougan M, Dougan SK. Roehle K, et al. Among authors: agudo j. Sci Transl Med. 2021 May 19;13(594):eabf5058. doi: 10.1126/scitranslmed.abf5058. Sci Transl Med. 2021. PMID: 34011631 Free PMC article.
Immune-Mediated Specific Depletion of Intestinal Stem Cells.
Sherman SE, Agudo J. Sherman SE, et al. Among authors: agudo j. Methods Mol Biol. 2020;2171:25-39. doi: 10.1007/978-1-0716-0747-3_2. Methods Mol Biol. 2020. PMID: 32705633
Thus, we generated a mouse model whose cytotoxic T cells recognize and kill GFP-expressing cells, called the Jedi (Agudo et al., Nat Biotechnol 33:1287-1292, 2015). Jedi T cells now enable the depletion of virtually almost any cell type by using a suitable GFP-expressing t …
Thus, we generated a mouse model whose cytotoxic T cells recognize and kill GFP-expressing cells, called the Jedi (Agudo et al., Nat …
Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati A, Kumar S, Jiang P, Pyrdol J, Zou AE, Godicelj A, Mathewson ND, Cartwright ANR, Cejas P, Brown M, Giobbie-Hurder A, Dillon D, Agudo J, Mittendorf EA, Liu XS, Wucherpfennig KW. Bagati A, et al. Among authors: agudo j. Cancer Cell. 2021 Jan 11;39(1):54-67.e9. doi: 10.1016/j.ccell.2020.12.001. Epub 2020 Dec 31. Cancer Cell. 2021. PMID: 33385331 Free PMC article.
The Immunology of Hormone Receptor Positive Breast Cancer.
Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL. Goldberg J, et al. Among authors: agudo j. Front Immunol. 2021 May 11;12:674192. doi: 10.3389/fimmu.2021.674192. eCollection 2021. Front Immunol. 2021. PMID: 34135901 Free PMC article. Review.
65 results